Benedetti Panici P, Scambia G, Massidda B, Chessa P, Tarquini A, Mancuso S
Oncology. 1986;43(4):208-11. doi: 10.1159/000226366.
Beta-thromboglobulin, a platelet-specific protein secreted into the plasma during the release reaction, was measured in 73 women with breast cancer, 10 women with dysplastic disease and 30 healthy female control subjects. 73% of patients with primary operable breast cancer and 65% with metastatic disease had levels above 40 ng/ml (control range 11-38 ng/ml). Among 2-6 months' postoperative patients without evidence of disease at the time of sampling, beta-thromboglobulin was raised in 75% of patients with nodal involvement and in 28% of patients without nodal involvement. Only 1 of 10 patients with benign disease showed abnormal beta-thromboglobulin concentration. Our results show that in a high percentage of breast cancer patients a state of ongoing in vivo platelet activation may be present. Furthermore, beta-thromboglobulin can be regarded as a potential tumor marker in breast cancer.
β-血小板球蛋白是在释放反应期间分泌到血浆中的一种血小板特异性蛋白，我们对73例乳腺癌女性患者、10例发育异常疾病女性患者和30名健康女性对照者进行了检测。原发性可手术乳腺癌患者中有73%以及转移性疾病患者中有65%的β-血小板球蛋白水平高于40 ng/ml（对照范围为11 - 38 ng/ml）。在术后2 - 6个月且采样时无疾病证据的患者中，有淋巴结受累的患者中有75%以及无淋巴结受累的患者中有28%的β-血小板球蛋白水平升高。10例良性疾病患者中只有1例β-血小板球蛋白浓度异常。我们的结果表明，高比例的乳腺癌患者体内可能存在持续的血小板激活状态。此外，β-血小板球蛋白可被视为乳腺癌的一种潜在肿瘤标志物。
